Study Utilizing Rilonacept in Gout Exacerbations
Public ClinicalTrials.gov record NCT00855920. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.
Study identification
- NCT ID
- NCT00855920
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 225 participants
Conditions and interventions
Conditions
Interventions
- Rilonacept Drug
- Indomethacin Drug
- Placebo (for Indomethacin) Other
- Placebo (for Rilonacept) Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2009 (Type not available)
- Primary completion
- Feb 2010 (Actual)
- Completion
- Feb 2010 (Actual)
- Last update posted
- Apr 28, 2017
2009 – 2010
United States locations
- U.S. sites
- 44
- U.S. states
- 19
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Mesa | Arizona | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Sierra Vista | Arizona | — | — |
| Not listed | Burbank | California | — | — |
| Not listed | Whittier | California | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | DeBary | Florida | — | — |
| Not listed | DeLand | Florida | — | — |
| Not listed | Jupiter | Florida | — | — |
| Not listed | Orange Park | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Oviedo | Florida | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Elizabethtown | Kentucky | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Wheaton | Maryland | — | — |
| Not listed | Detroit | Michigan | 48221 | — |
| Not listed | Stevenville | Michigan | — | — |
| Not listed | Billings | Montana | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | Burlington | North Carolina | — | — |
| Not listed | Cary | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | 27612 | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Willoughby Hills | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Lake Oswego | Oregon | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Johnstown | Pennsylvania | — | — |
| Not listed | Limerick | Pennsylvania | — | — |
| Not listed | Norristown | Pennsylvania | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Bristol | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Forth Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Irving | Texas | — | — |
| Not listed | Mesquite | Texas | — | — |
| Not listed | North Richland Hills | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00855920, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2017 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00855920 live on ClinicalTrials.gov.